Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab 2017;19:1322-1326Norton, Luke,Shannon,etc.Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic...
3) Glucose transport protein 葡萄糖转运蛋白 1. Three kinds of cells were treated with emodin and rhein, and the PPARγ and glucose transport protein ( GLUT ) proteins expression levels were evaluated by Western blot analysis. 将大黄素和大黄酸与诱导成熟的可用于实验的细胞进行培养,Western杂交法...
The transport of glucose from the tubule into the tubular epithelial cells is accomplished by sodium-glucose co-transporters (SGLTs). SGLTs encompass a family of membrane proteins that are responsible for the transport of glucose, amino acids, vitamins, ions and osmolytes across the brush-border ...
Na+/glucose cotransporters (SGLTs) are responsible for the “secondary-active” transport of glucose and other substrates across cellular membranes. They concentrate glucose inside the cell using electrochemical energy from the transmembrane Na+gradient, employing an alternating access cotransport mechanism....
1.Sodium-glucose co-transporters(SGLT) are a family of glucose transporter found in the intestinal mucosa of the small intestine(SGLT) and the proximal tubule of the nephron(SGLT2 and SGLT1).钠-葡萄糖协同转运蛋白(SGLT)是一类在小肠粘膜(SGLT1)和肾近曲小管(SGLT2和SGLT1)中发现的葡萄糖转运基因...
Sodium-glucose co-transport inhibitors: prog- ress and therapeutic potential in type 2 diabetes mellitus. Drugs 2010;70:377-385Neumiller JJ,White J,Campbell RK.Sodium-Glucose Co-Transport inhibitors progress and therapeutic potential in type 2 diabetes mellitus[J].Drugs,2010,70(4):377-385....
Sodium-Glucose Co-Transporter 2 Inhibitors and Heart Failure Background: The 2022 Canadian Cardiovascular Society (CCS) cardiorenal guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibit... A Gass - 《American Journal of Medicine》 被引量: 0发表: 2024年 Implementation of...
Sodium鈥揼lucose co-transporter 2 (SGLT2) inhibitors are the newest class of medication for T2DM and provide an alternative, insulin-independent, pathway for addressing hyperglycaemia, by reducing renal glucose reabsorption. SGLT2 inhibitors are associated with a low risk of hypoglycaemia and recent ...
Clinically important improvements in cardiovascular risk factors and adverse cardiovascular, heart failure and renal outcomes have been observed in numerous cardiovascular outcome trials (CVOTs) investigating the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors over the last 5 years. However, ...
The sodium-glucose transporter 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin are recently approved medications for type 2 diabetes. Recent studies indicate the potential ability of SGLT2 inhibitors to attenuate cancer growth of SGLT2-expressing cancer cells, but there is little known about the ...